Numinus Wellness Inc. (TSXV:NUMI), a Canadian healthcare stock, jumped after receiving Health Canada approval to research extraction of psilocybin from mushrooms
‘Magic’ mushrooms research pushed a Canadian healthcare stock higher Thursday. Here’s some small stocks making big moves on Thursday, June 11, 2020 (as of 4 pm EST):
Numinus Wellness Inc. (TSXV:NUMI), a Canadian healthcare stock, gained as much as 12% on Thursday after announcing that it has received Health Canada approval to amend the Company’s existing License under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms.
As well, shares of Great Bear Resources Ltd. (TSXV:GBR) rose 3% to $12.53 as the gold junior released additional drill results from its flagship Dixie Project in the Red Lake district of Ontario, which included 31.33 grams per tonne (g/t) gold over 20.55 metres.
HEXO Corp. (TSX:HEXO), meanwhile, reported better-than-expected Q3 2020 revenue that rose 30% quarter over quarter to $22.1 million. HEXO stock moved up as much as 10% following the announcement.
Finally, First Mining Gold Corp. (TSX:FF) shares added as much as 5% after the resource junior announced that First Majestic Silver will pay the Company US$22.5 million for the right to purchase 50% of the payable silver produced from Springpole Gold Project in Ontario for the lifetime of the Project.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Numinus Wellness Inc. (TSXV:NUMI), a Canadian healthcare stock, gained as much as 12% on Thursday after announcing that it has received Health Canada approval to amend the Company’s existing License under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms.
, on Thursday.){kind=link}